| 1 |
Rossetti L, Iester M, Tranchina L, Ottobelli L, Coco G, Calcatelli E, Ancona C, Cirafici P, Manni G. Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial. J Glaucoma 2020;29:513-20. [PMID: 32541370 DOI: 10.1097/IJG.0000000000001565] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 2 |
Oddone F, Rossetti L, Parravano M, Sbardella D, Coletta M, Ziccardi L, Roberti G, Carnevale C, Romano D, Manni G, Parisi V. Citicoline in Ophthalmological Neurodegenerative Disease: A Comprehensive Review. Pharmaceuticals (Basel) 2021;14:281. [PMID: 33804675 DOI: 10.3390/ph14030281] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 3 |
Gandolfi S, Marchini G, Caporossi A, Scuderi G, Tomasso L, Brunoro A. Cytidine 5'-Diphosphocholine (Citicoline): Evidence for a Neuroprotective Role in Glaucoma. Nutrients 2020;12:E793. [PMID: 32197303 DOI: 10.3390/nu12030793] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 4 |
Parravano M, Scarinci F, Parisi V, Giorno P, Giannini D, Oddone F, Varano M. Citicoline and Vitamin B12 Eye Drops in Type 1 Diabetes: Results of a 3-year Pilot Study Evaluating Morpho-Functional Retinal Changes. Adv Ther 2020;37:1646-63. [PMID: 32180131 DOI: 10.1007/s12325-020-01284-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 5 |
Dal Monte M, Cammalleri M, Amato R, Pezzino S, Corsaro R, Bagnoli P, Rusciano D. A Topical Formulation of Melatoninergic Compounds Exerts Strong Hypotensive and Neuroprotective Effects in a Rat Model of Hypertensive Glaucoma. Int J Mol Sci 2020;21:E9267. [PMID: 33291737 DOI: 10.3390/ijms21239267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 6 |
Tundo GR, Sbardella D, Santoro AM, Coletta A, Oddone F, Grasso G, Milardi D, Lacal PM, Marini S, Purrello R, Graziani G, Coletta M. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges. Pharmacol Ther 2020;213:107579. [PMID: 32442437 DOI: 10.1016/j.pharmthera.2020.107579] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 7 |
Sbardella D, Coletta A, Tundo GR, Ahmed IMM, Bellia F, Oddone F, Manni G, Coletta M. Structural and functional evidence for citicoline binding and modulation of 20S proteasome activity: Novel insights into its pro-proteostatic effect. Biochem Pharmacol 2020;177:113977. [PMID: 32298691 DOI: 10.1016/j.bcp.2020.113977] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 8 |
Parisi V, Ziccardi L, Barbano L, Giorno P, Varano M, Parravano M. Citicoline and Vitamin B12 Eye Drops in Type 1 Diabetes: Results of a 36-Month Pilot Study Evaluating Macular Electrophysiological Changes. Adv Ther 2021;38:3924-36. [PMID: 34091874 DOI: 10.1007/s12325-021-01771-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 9 |
Antimisiaris SG, Marazioti A, Kannavou M, Natsaridis E, Gkartziou F, Kogkos G, Mourtas S. Overcoming barriers by local drug delivery with liposomes. Adv Drug Deliv Rev 2021;174:53-86. [PMID: 33539852 DOI: 10.1016/j.addr.2021.01.019] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 50.0] [Reference Citation Analysis]
|
